SynthesisBritish journal of cancer2015
Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma.
Synthesis in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Systematic review and validation of clinical models predicting survival after oesophagectomy for adenocarcinoma.The British journal of surgery · 2022Pooled it
- Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review.BMJ open · 2018Pooled it
- Inflammatory Biomarkers from Blood Counts as Prognostic Tools in Metastatic Esophageal Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- The tumour immune microenvironment in oesophageal cancer.British journal of cancer · 2021Review
- Article
- A non-linear optimisation method to extract summary statistics from Kaplan-Meier survival plots using the published P value.BMC medical research methodology · 2020Article
- Article
- Alcohol intake, tobacco smoking, and esophageal adenocarcinoma survival: a molecular pathology epidemiology cohort study.Cancer causes & control : CCC · 2020Article
- The Cancer-Immune Set Point in Oesophageal Cancer.Frontiers in oncology · 2020Review
- Cyclo-oxygenase-2 expression is associated with mean standardised uptake value on 18F-Fluorodeoxyglucose positron emission tomography in oesophageal adenocarcinoma.The British journal of radiology · 2019Article
- The use of digital pathology and image analysis in clinical trials.The journal of pathology. Clinical research · 2019Article
- Article
- Prognostic value of an immunohistochemical signature in patients with esophageal squamous cell carcinoma undergoing radical esophagectomy.Molecular oncology · 2018Article
- Pattern of p53 protein expression is predictive for survival in chemoradiotherapy-naive esophageal adenocarcinoma.Oncotarget · 2017Article
- Loss of SRY-box2 (SOX2) expression and its impact on survival of patients with oesophageal adenocarcinoma.The British journal of surgery · 2017Article
- Future directions in esophageal cancer therapy.Annals of cardiothoracic surgery · 2017Article
- RAINFALL before RAINBOW-an illusion or reality?Translational gastroenterology and hepatology · 2017Article
- Genetic predisposition and prediction protocol for epithelial neoplasms in disease-free individuals: A systematic review.Journal of oral and maxillofacial pathology : JOMFPArticle
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
backgroundOesophageal adenocarcinoma (OAC) is one of the fastest rising malignancies with continued poor prognosis. Many studies have proposed novel biomarkers but, to date, no immunohistochemical markers of survival after oesophageal resection have entered clinical practice. Here, we systematically review and meta-analyse the published literature, to identify potential biomarkers.
methodsRelevant articles were identified via Ovid medline 1946-2013. For inclusion, studies had to conform to REporting recommendations for tumor MARKer (REMARK) prognostic study criteria. The primary end-point was a pooled hazard ratio (HR) and variance, summarising the effect of marker expression on prognosis.
resultsA total of 3059 articles were identified. After exclusion of irrelevant titles and abstracts, 214 articles were reviewed in full. Nine molecules had been examined in more than one study (CD3, CD8, COX-2, EGFR, HER2, Ki67, LgR5, p53 and VEGF) and were meta-analysed. Markers with largest survival effects were COX-2 (HR=2.47, confidence interval (CI)=1.15-3.79), CD3 (HR=0.51, 95% CI=0.32-0.70), CD8 (HR=0.55, CI=0.31-0.80) and EGFR (HR=1.65, 95% CI=1.14-2.16). DISCUSSION: Current methods have not delivered clinically useful molecular prognostic biomarkers in OAC. We have highlighted the paucity of good-quality robust studies in this field. A genome-to-protein approach would be better suited for the development and subsequent validation of biomarkers. Large collaborative projects with standardised methodology will be required to generate clinically useful biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.